Ameriprise Financial Inc. Has $8.07 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Ameriprise Financial Inc. lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 205,173 shares of the company’s stock after acquiring an additional 18,412 shares during the period. Ameriprise Financial Inc.’s holdings in CRISPR Therapeutics were worth $8,072,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Intellectus Partners LLC raised its stake in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares in the last quarter. Farrow Financial Inc. raised its stake in shares of CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after purchasing an additional 270 shares in the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after purchasing an additional 372 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC raised its stake in shares of CRISPR Therapeutics by 4.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company’s stock valued at $420,000 after purchasing an additional 443 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares in the company, valued at approximately $7,673,353.80. This represents a 5.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,021 shares of company stock worth $594,771. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on CRSP shares. Citigroup dropped their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Barclays dropped their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research note on Friday, May 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $71.75.

CRISPR Therapeutics Stock Down 5.8%

CRISPR Therapeutics stock opened at $36.99 on Thursday. The business’s 50-day simple moving average is $37.24 and its 200 day simple moving average is $42.19. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -8.46 and a beta of 1.88. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the firm posted ($1.43) EPS. The firm’s revenue for the quarter was up 71.6% on a year-over-year basis. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.